Skip to content

Clinical study of Qiliqiangxin capsule in preventing acute kidney injury induced by contrast agent

Clinical study of Qiliqiangxin capsule in preventing acute kidney injury induced by contrast agent

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047867
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast-induced acute kidney injury

Interventions

Qiliqiangxin capsule group:Qiliqiangxin capsule group was administered 2 days before surgery, 3 capsules each time, 3 times a day, and continued to be applied to the third day after surgery, totaling

Sponsors

Department of Cardiology, Zhongda Hospital of Southeast University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in this trial and sign the informed consent; 2. Aged 18 to 80 years old; 3. Proposed coronary stent implantation; 4.AGEF score>1.16; 5. Not taking Qili Qiangxin Capsules or Chinese patent medicines with similar ingredients in the past month; 6. Those who can wait more than 1 week for elective secondary PCI after selection.

Exclusion criteria

Exclusion criteria: 1. Have a history of allergy to Qili Qiangxin Capsules or similar components of proprietary Chinese medicines; 2. Acute ST-segment elevation myocardial infarction (STEMI); 3. NYHA cardiac function class IV, unstable hemodynamics, unable to lie supine for more than 24 hours; 4. Those who have taken Qili Qiangxin Capsules or Chinese patent medicines with similar ingredients within 14 days before enrollment; 5. CT, MRI angiography and other examinations with contrast agents within 14 days before enrollment; it is expected that imaging examinations with other contrast agents will be required during the study period (except for elective PCI after 1 week, which requires the use of the same contrast agent); 6. Blood pressure lower than 120/80mmHg; 7. Abnormal liver function, ALT > 3 times the upper limit of normal; 8. Thyroid dysfunction; 9. Malignant tumors, inflammatory diseases, autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
Incidence of contrast-induced acute kidney injury;

Secondary

MeasureTime frame
Secondary Outcome Measures;

Countries

China

Contacts

Public ContactYan Gaoliang

Department of Cardiology, Zhongda Hospital of Southeast University Medical School

yanshipingguo@163.com+86 18761890380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026